Gold prices buoyed by tariff fears; US duties on 1-kilo bars spur supply concerns
SOUTH SAN FRANCISCO - Aligos Therapeutics, Inc. (NASDAQ: ALGS), a clinical-stage biotech company whose stock has declined nearly 78% over the past year according to InvestingPro data, has presented positive data from its clinical programs at the European Association for the Study of the Liver (EASL) Congress 2025, which could potentially position its therapies as leading treatments for liver and viral diseases.
The data highlighted the sustained efficacy of ALG-000184, a capsid assembly modulator, in treating chronic hepatitis B virus (HBV) infection. According to the results, all subjects in both the HBeAg+ and HBeAg- cohorts achieved HBV DNA viral suppression to below the lower limit of quantification (LLOQ) and showed consistent reductions in viral antigens over 96 weeks of treatment. With a current market capitalization of just $26.7 million and a strong current ratio of 2.86, InvestingPro data shows the company maintains solid liquidity despite ongoing R&D investments.
In the HBeAg+ cohort, a significant reduction in HBV DNA was seen, with all subjects achieving viral suppression by week 96. Similarly, all HBeAg- subjects reached and maintained viral suppression by week 24, which persisted through week 96 without any observed viral breakthrough. The study also reported no known CAM resistant mutations in subjects treated with ALG-000184 monotherapy.
Furthermore, Aligos showcased the potential of ALG-055009, a thyroid hormone receptor beta agonist, in treating metabolic dysfunction-associated steatohepatitis (MASH). The treatment demonstrated significant reductions in liver fat content and atherogenic lipids over a 12-week period, which could benefit patients at risk for cardiovascular disease.
The presentations at the EASL Congress underscore Aligos’ commitment to advancing its pipeline of therapeutics. These developments could have a significant impact on the treatment landscape for chronic HBV infection and MASH, offering hope for improved patient outcomes. InvestingPro analysis suggests the stock is currently trading below its Fair Value, with 12 additional ProTips available to subscribers, including detailed insights on the company’s financial health and growth prospects.
The data presented is based on a press release statement from Aligos Therapeutics and has not been independently verified. Aligos Therapeutics is a clinical stage biotechnology company dedicated to developing therapies for unmet medical needs in liver and viral diseases.
In other recent news, Aligos Therapeutics announced a private placement agreement expected to generate approximately $105 million, extending the company’s cash runway into the second half of 2026. This transaction involves selling over 2 million shares of common stock, including both voting and non-voting shares, alongside pre-funded and accompanying warrants. The funding will be used to advance ALG-000184 into a Phase 2 clinical study for chronic hepatitis B virus infection and other corporate purposes. Jefferies and Piper Sandler are acting as placement agents, while H.C. Wainwright & Co. is serving as a financial advisor for the transaction.
Additionally, H.C. Wainwright analyst Ed Arce recently adjusted the price target for Aligos Therapeutics to $70 from the previous $75, maintaining a Buy rating. This follows the presentation of promising data from a Phase 1 study of ALG-000184, a treatment for chronic Hepatitis B, at The Liver Meeting in 2024. The interim results demonstrated sustained suppression of HBV DNA, forming the basis for continued research and development. Aligos plans to present further data at upcoming conferences, including the EASL Congress in Amsterdam and the AASLD TLM in Washington, DC. These developments are closely watched by investors, given their potential impact on the company’s future and benefits for patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.